Sanofi-Aventis to pay more than $20 bil. for Genzyme

French and American flags fly outside the New York Stock Exchange after officials of French pharmaceutical company Sanofi-aventis rang the opening bell.

TEXT OF STORY

STEVE CHIOTAKIS: The French pharmaceutical giant Sanofi-Aventis will pay $20 billion for Genzyme, that's an American biotech firm based in Massachusetts.

The BBC's Jon Bithrey is in London. He has more on this mega-deal that's sure to make some waves. Hi Jon.

JON BITHREY: Hello Steve.

CHIOTAKIS: Now why has this French firm picked up Genzyme? What do they want with Genzyme?

BITHREY: Well Sanofi-Aventis is France's biggest drug maker and it's been after Genzyme for a while. Largely because Sanofi doesn't have many new drugs of its own in the pipeline and it's facing competition from generic producers. Genzyme makes a lot of treatments for rare diseases. Its best selling drug Cerezyme treats liver and neurological problems. It's also producing a new range of drugs for high cholesterol.

CHIOTAKIS: $20 billion, Jon, is a lot of money. Is this a good deal for Sanofi?

BITHREY: Well not as good as it would have liked. It launched a hostile bid last September for $18.5 billion. That failed and it's had to up that to more than $20 billion to get the board to agree. But Genzyme did have some production glitches of its best selling drugs a couple of years back and that pulled down its value, making it more vulnerable to a takeover. But this is still the biggest deal in the drug industry since Merck bought Schering Plough in 2009.

CHIOTAKIS: The BBC's Jon Bithrey in London. Jon thank you.

BITHREY: Thank you Steve.

About the author

Steve Chiotakis was the host of Marketplace Morning Report until January 2012.

Comments

I agree to American Public Media's Terms and Conditions.
With Generous Support From...